Zhangfeng Zhong

2.6k citations
54 papers · 2.0k indexed · 1 hit paper · h-index 23

Zhangfeng Zhong

53 papers receiving 2.0k citations

Hit Papers

Naturally occurring anti-cancer compounds: shining from C...4122019202620212023100200300400

Peers

Zhangfeng Zhong
Comparison fields: 5 of 114
  • Pharmacology 288
  • Complementary and alternative medicine 237
  • Pharmacology 416
  • Molecular Medicine 88
  • Cancer Research 246
Replace Bertrand Liagre with:
Bertrand Liagre France
Xueting Cai China
Minghai Tang China
Ahmed M. Al‐Abd Egypt
Afzal Hussain Saudi Arabia
Tao Li China
Jing Xie China
Parama Dey India
José Manuel Calderón‐Montaño Spain
Zhangfeng Zhong relative to Bertrand Liagre France Bertrand Liagre's profile →
Citations per field
00.5×1.5×2.3×
Bertrand Liagre · 1×
Citations per year

Countries citing papers authored by Zhangfeng Zhong

Since Specialization
Citations

This map shows the geographic impact of Zhangfeng Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhangfeng Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhangfeng Zhong more than expected).

Fields of papers citing papers by Zhangfeng Zhong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhangfeng Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhangfeng Zhong. The network helps show where Zhangfeng Zhong may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Zhangfeng Zhong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zhangfeng Zhong Line = papers co-authored together Zhangfeng Zhong links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20257
2 20251
3 202413
4 202415
5 202427
6 202425
7 202318
8 20234
9 20234
10 202320
11 20224
12 202235
13 20226
14 202279
15 202222
16 202232
17 202048
18 202017
19 202037
20 202061

About Zhangfeng Zhong

Zhangfeng Zhong is a scholar working on Pharmacology, Cancer Research and Molecular Medicine, having authored 54 papers that have together received 2.0k indexed citations. Recurring topics across this work include Magnetic properties of thin films (4 papers), Pharmacological Effects of Natural Compounds (4 papers), Surface and Thin Film Phenomena (4 papers), Toxin Mechanisms and Immunotoxins (3 papers), NF-κB Signaling Pathways (3 papers), Quantum and electron transport phenomena (3 papers), Natural product bioactivities and synthesis (3 papers) and Phytochemicals and Antioxidant Activities (3 papers). The work is most often cited by research in Pharmacology (288 citations), Complementary and alternative medicine (237 citations) and Pharmacology (416 citations). Zhangfeng Zhong has collaborated with scholars based in China, Macao and Hong Kong. Frequent co-authors include Yitao Wang, Yitao Wang, Zengtao Xu, Xiuping Chen, Lidian Chen, Chi Teng Vong, Shengpeng Wang, Ning Wang, Yibin Feng and Hor‐Yue Tan. Their work appears in journals such as SHILAP Revista de lepidopterología, Nano Letters and ACS Nano.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026